bluebird bio Inc. will have an eventful 2020, including the submission of three different products for regulatory approvals, but at least one milestone will be reached a little later than previously expected.
The company launched its gene therapy Zynteglo (autologous CD34+ cells encoding βA-T87Q-globin gene) in the EU, where it was approved for transfusion-dependent beta-thalassemia (TDT) in June, and will treat its...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?